| |
KOMISJA NADZORU FINANSOWEGO |
|
| |
|
|
Raport bieżący nr |
3 |
/ |
2020 |
|
|
|
| |
Data sporządzenia: |
2020-01-20 |
|
|
|
|
|
|
|
|
|
| |
Skrócona nazwa emitenta |
|
|
|
|
|
|
|
|
|
| |
MILESTONE MEDICAL |
|
| |
Temat |
|
|
|
|
|
|
|
|
|
|
| |
Receiving a Notice of Allowance for U.S Patent related to Cosmetic Injection System |
|
| |
Podstawa prawna |
|
|
|
|
|
|
|
|
| |
Art. 17 ust. 1 MAR - informacje poufne.
|
|
| |
Treść raportu: |
|
|
|
|
|
|
|
|
|
| |
The Board of Directors of Milestone Medical Inc. _WAR: MMD, “the Company", “the Issuer"_,
today announced that Milestone Scientific, Inc., _NYSE: MLSS_, the majority shareholder
and licensor of Milestone Medical Inc., has received a Notice of Allowance from the
United States Patent and Trademark Office _USPTO_ for a U.S. patent regarding a new
application for its technology in which claims were allowed for a Computer Controlled
Drug Infusion Device for cosmetic use. The allowed claims relate to a novel cosmetic
injection instrument for the delivery of botulinum toxin, such as Botox® and Dysport®.
The CompuFlo® system with DPS Dynamic Pressure Sensing _DPS®_ Technology® provides
an objective tool that can consistently reduce pain perception, accurately maintain
a precise unit dose of botulinum toxin and allows the graphic recording of unit doses
for each patient, while allowing the clinician to generate a precise record for future
use. Additionally, the patented hand piece design provides for greater tactile feel
for precise needle manipulation and placement. The system is optimized for a faster,
more precise and virtually painless experience for the patient while providing clinicians
with an important graphic recording of the procedure.
The Board of Directors of the Company is pleased to receive the Notice of Allowance
related to the cosmetic injection system, as this expands the intellectual property
into an exciting new application. Based on the Issuer’s previous feasibility study
of plastic surgeons and cosmetic dermatologists, the Company recognized the profession’s
interest in a new cosmetic injection system that would allow the delivery of precise
dosage and address the need for a unique graphic record.
With this patent in hand, The Board of Directors of the Company looks forward to advancing
the commercial roll-out of the cosmetic injection instrument in the U.S., which has
the potential to significantly impact the safety and administration of botulinum toxin.
The market opportunity for the cosmetic instrument includes over 8.4 million botulinum
toxin injections delivered annually in the U.S. alone.
|
|
|
RB_ASO: Receiving a Notice of Allowance for U.S Patent related to Cosmetic Injection System
